A detailed history of Ameriprise Financial Inc transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Ameriprise Financial Inc holds 37,489 shares of LYEL stock, worth $26,242. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,489
Holding current value
$26,242
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$0.59 - $1.48 $22,118 - $55,483
37,489 New
37,489 $23,000
Q3 2023

Nov 14, 2023

BUY
$1.45 - $3.35 $65,165 - $150,555
44,942 New
44,942 $66,000
Q1 2023

May 15, 2023

BUY
$1.97 - $3.58 $447,087 - $812,473
226,948 New
226,948 $535,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $173M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.